Arvinas (ARVN)

Executive Summary

Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation through its proprietary PROTAC platform. The company is developing a pipeline of novel small molecules that harness the cell's own degradation machinery to eliminate disease-causing proteins, including those previously considered undruggable. Arvinas's lead candidate, ARV-110 (bavdegalutamide), targeting the androgen receptor in metastatic prostate cancer, has completed Phase 1/2 trials, though further development may depend on combination strategies. The company's pipeline also includes ARV-806, a first-in-class PROTAC degrader of KRAS G12D, which is currently in Phase 1/2, and ARV-393, a BCL6 degrader for B-cell non-Hodgkin lymphoma in Phase 1 in combination with glofitamab. With a public listing (NASDAQ: ARVN) and a market cap of approximately $685 million, Arvinas represents a high-risk, high-reward investment opportunity in the precision oncology space. Arvinas's core competitive advantage lies in its PROTAC Discovery Engine, which has demonstrated the ability to target proteins beyond the reach of traditional small molecules. While the completion of ARV-110 monotherapy trials raises questions about its path to registration, the company's next-generation candidates, particularly ARV-806 (KRAS G12D) and ARV-393 (BCL6), have garnered significant scientific interest. Data from ongoing Phase 1/2 trials will be critical in validating the broader potential of the PROTAC platform beyond androgen receptor degradation. The company's valuation and stage of development suggest that upcoming clinical readouts could drive substantial volatility and upside if positive.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 data for ARV-806 (KRAS G12D) in advanced solid tumors65% success
• Q4 2026Phase 1 dose-escalation data for ARV-393 + glofitamab in R/R B-cell NHL70% success
• TBDUpdate on ARV-110 combination trial with abiraterone50% success